SCHEMBL3592894

SCHEMBL3592894

CC1Oc2ccc(NC(=O)/C=C3\CC(C)(C)Oc4cc(C(F)(F)F)ccc43)cc2NC1=O

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 18/20 0.45
TP53 P04637 1/20 0.36
SMYD3 Q9H7B4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598440 0.90 TRPV1 (0.47) TRPV1
SCHEMBL3589992 0.90 TRPV1 (0.38) TRPV1SMYD3
SCHEMBL3594536 0.88 TRPV1 (0.48) TRPV1
SCHEMBL3593401 0.88 RAF1 (0.43) TRPV1
SCHEMBL3603202 0.85 TRPV1 (0.42) TRPV1SMYD3
SCHEMBL3593350 0.82 TRPV1 (0.59) TRPV1
SCHEMBL3597114 0.82 TRPV1 (0.43) TRPV1TP53
SCHEMBL3587874 0.80 TRPV1 (0.53) TRPV1
SCHEMBL3597958 0.79 TRPV1 (0.42) TRPV1TP53
SCHEMBL3602172 0.79 TRPV1 (0.47) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885TP53 3619/4885SMYD3 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.